Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 6/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CENPE | Q02224 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238106 | 0.89 | DPP4 (0.53) | DPP4TACR1 | |
| SCHEMBL7174997 | 0.87 | DPP4 (0.54) | DPP4CYP3A4TACR1 | |
| SCHEMBL5240910 | 0.84 | DPP4 (0.59) | DPP4CYP3A4TACR1CENPEDHODH | |
| SCHEMBL5233643 | 0.83 | DPP4 (0.59) | DPP4TACR1 | |
| SCHEMBL5237066 | 0.83 | DPP4 (0.56) | DPP4TACR1 | |
| SCHEMBL5236772 | 0.83 | DPP4 (0.60) | DPP4CYP3A4TACR1 | |
| SCHEMBL6110970 | 0.82 | DPP4 (0.77) | DPP4CYP3A4TACR1 | |
| SCHEMBL8947817 | 0.81 | DPP4 (0.55) | DPP4TACR1 | |
| Hydrochloric Acid SCHEMBL5236244 | 0.81 | DPP4 (0.76) | DPP4CYP3A4TACR1 | |
| SCHEMBL5235258 | 0.81 | DPP4 (0.53) | DPP4TACR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885CYP3A4 663/4885TACR1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.